May 2026 $28 M No. 4 $10 to $50 million 33
Allyx Therapeutics, Inc.: Raise no. 4, May 2026 × Investors in this round 33 investors had bought by the notice of Oct 21, 2026: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $28 M of $30 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $328,671
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Stephen Bloch · Executive Officer, Director Timothy Siegert · Executive Officer Gregory P Ho · Director Kevin L. Rakin · Director Paul Fonteyne · Director Robert A Bettigole · Director Stephen Strittmatter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Supervision Partners LLC (CRD 300528) · New York, New York Sold in AL, CA, CO, CT, DE, FL, GA, HI, IL, IA, KY, ME, MA, MI, MN, MO, NV, NH, NJ, NY, NC, OH, OK, PA, RI, SC, TN, TX, UT, VA, WA, WI, and outside the US Remarks in the notice On the use of proceeds: “No amount other than ordinary course employment compensation is being paid to officers and directors.”Signed by Dr. Stephen Bloch, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 21, 2026. Read the notice at the SEC .
equity, options SEC Feb 2026 $3 M No. 3 $2 to $10 million 12
Allyx Therapeutics, Inc.: Raise no. 3, Feb 2026 × Investors in this round 12 investors had bought by the notice of Mar 3, 2026: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, other: Simple Agreements for Future Equity (SAFEs) Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jennifer A Gabler · Executive Officer Stephen Bloch · Executive Officer, Director Timothy A Siegert · Executive Officer Gregory P Ho · Director Paul Fonteyne · Director Robert A Bettigole · Director Stephen Strittmatter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “No amount other than ordinary course employment compensation is being paid to officers and directors.”Signed by Dr. Stephen Bloch, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 3, 2026. Read the notice at the SEC .
options SEC Feb 2023 $2 M No. 2 $2 to $10 million 11
Allyx Therapeutics, Inc.: Raise no. 2, Feb 2023 × Investors in this round 11 investors had bought by the notice of Feb 10, 2023: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Stephen Bloch · Executive Officer, Director Timothy P. Siegert · Executive Officer Gregory P. Ho · Director Paul P. Fonteyne · Director Robert A. Bettigole · Director Stephen Strittmatter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”Signed by Dr. Stephen Bloch, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 10, 2023. Read the notice at the SEC .
equity SEC May 2021 $8 M No. 1 $2 to $10 million 10
Allyx Therapeutics, Inc.: Raise no. 1, May 2021 × Investors in this round 10 investors had bought by the notice of Jun 2, 2021: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Stephen Bloch · Executive Officer, Director Stephen Strittmatter · Executive Officer, Director Timothy P. Siegert · Executive Officer Gregory P. Ho · Director Paul P. Fonteyne · Director Robert A. Bettigole · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”Signed by Dr. Stephen Bloch, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 2, 2021. Read the notice at the SEC .
equity SEC